• Hua Medicine annual report for fiscal 2025 highlighted rapid scale-up of in-house commercialization for diabetes drug dorzagliatin in mainland China from Jan. 1, 2025.
• Sales execution expanded nationwide through 10 sales regions, supported by an internal team of 130 product representatives.
• Operational focus shifted to an AI-enabled digital commercialization platform, targeting higher sales productivity.
• Manufacturing optimization lifted gross margin to 56.9%.
• Company secured Hong Kong regulatory clearance for dorzagliatin commercialization on Feb. 27, 2026, targeting a mid-2026 launch under trade name MYHOMSIS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hua Medicine published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260422-12116512), on April 22, 2026, and is solely responsible for the information contained therein.